Barclays raised its price target on Hims & Hers Health to $39 from $29 while maintaining an Overweight rating, citing expected revenue and EBITDA momentum in the second half of 2026 driven by weight-loss offerings and other business areas. The firm noted that the stock could see further upside as investor confidence grows following the partnership announcement with Novo Nordisk. Separately, Hims & Hers completed its acquisition of Eucalyptus, expanding its global consumer healthcare platform into the United Kingdom, Australia, and Canada alongside its existing US operations.
Hims Hers Health IncBarclays raised price target to $39 and maintained Overweight rating, citing expected revenue and EBITDA momentum.
Barclays PLC
Novo Nordisk A/S